Provided by Tiger Trade Technology Pte. Ltd.

Arvinas Holding Company LLC

7.71
+0.20002.66%
Volume:204.83K
Turnover:1.56M
Market Cap:504.13M
PE:57.68
High:7.71
Open:7.46
Low:7.46
Close:7.51
52wk High:14.51
52wk Low:6.97
Shares:65.39M
Float Shares:56.67M
Volume Ratio:0.52
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1337
EPS(LYR):-1.1400
ROE:1.59%
ROA:-1.01%
PB:0.90
PE(LYR):-6.76

Loading ...

Arvinas: Findings Support Evaluation of Arv-102 as a Therapeutic Approach for Neurodegenerative Diseases Associated with Lrrk2 Dysregulation

THOMSON REUTERS
·
Oct 07

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of Arv-102 in Patients with Parkinson’s Disease

THOMSON REUTERS
·
Oct 07

Arvinas : Phase 1 Arv-102 Showed Dose-Dependent Improvements in Eye Movement in Parkinson's Patients

THOMSON REUTERS
·
Oct 07

Arvinas Reports Phase 1 Parkinson’s Trial Data Showing ARV-102-Linked Gains in Oculomotor Measure

Reuters
·
Oct 07

Arvinas to Present Phase 1 Biomarker Data for ARV-102 Parkinson’s Trial at 2026 MDS Congress

Reuters
·
Oct 02

Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Reuters
·
Oct 01

Arvinas Grants New Hire Stock Option for 64,766 Shares, 42,388 RSUs Under NASDAQ Inducement Rule

Reuters
·
Sep 30

Arvinas Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 30

Arvinas Doses First Patient in Phase 1/2 Trial of HPK1 Degrader ARV-6723 in Advanced Solid Tumors

Reuters
·
Sep 28

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of Arv-6723, the Company’s First Immuno-Oncology Candidate

THOMSON REUTERS
·
Sep 28

Arvinas Grants 45,696 RSUs to Newly Hired Employee Under NASDAQ Inducement Award Plan

Reuters
·
Sep 02

Arvinas Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 02

Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Arvinas Price Target Cut to $21.00/Share from $24.00 by Citigroup

Dow Jones
·
Aug 10

Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

TIPRANKS
·
Aug 10

Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating

MT Newswires Live
·
Aug 10

Arvinas Posts Corporate Presentation Highlighting Protac Degrader Pipeline in Oncology and Neurology

Reuters
·
Aug 07

Arvinas Launches New Cancer Combo Trial, Adding Fresh Optionality to ARVN

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)

TIPRANKS
·
Aug 05

Arvinas, Inc. : Wells Fargo Cuts to Equal Weight from Overweight

THOMSON REUTERS
·
Aug 05